Of note, over the last years, an array of unimolecular GLP1-based poly-agonists, with different mechanisms of action, have been developed and experimentally validated for the treatment of metabolic syndrome, holding superior efficacy relative to conventional GLP1-RA 33,34,35
Several basic molecular and cellular mechanisms are shared among brain diseases, such as neuroinflammation, oxidative stress, excitotoxicity, neurodegeneration, disorders of neurogenesis, dysfunction of neurotrophic factor systems, which are most prominent in specific brain structures associated with different brain diseases [104, 105]
Always follow the specific storage instructions on the IMP label or trial protocol
All experimental procedures complied with national and international guidelines for the care and use of laboratory animals
Keep Meal Timing Consistent GLP-1 medications reduce appetite